Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.

The entities involved

• Hoffmann-La Roche →

  Swiss healthcare company

  • Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
  • Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08
• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.Sun 22:22
• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09